FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2566366120> ?p ?o ?g. }

• W2566366120 abstract "Abstract BACKGROUND: The outcome of patients with advanced stage Follicular Lymphoma (FL) has improved over the last decade, with the use of monoclonal antibodies (mAbs). The watch and wait approach (WW) in FL with low tumor burden was assumed when treatment options were limited and less effective than nowadays. In FL patients with indolent disease characterized by multiple relapses evolution, the therapeutic strategy should take into consideration the quality and duration of response and the impact on overall survival (OS) versus the risk of long-term toxicity. AIMS: Evaluation of the impact of WW approach compared with chemotherapy (CT) in time to next treatment (TNT), progression-free survival (PFS) and OS. METHODS: Retrospective study of 213 patients with FL, followed in a cancer care center between 2000-2012. Of these, 79 asymptomatic patients at diagnosis, with Ann Arbor stage III-IV were included and divided in 2 subgroups: 58 patients received the first-line treatment and 21 remained in surveillance. Tumor burden defined according to criteria of the Groupe d'Etude des Lymphomes Folliculaires (GELF). Survival analysis using the Kaplan-Meier method. Type of response defined according to NCCN criteria. RESULTS: Median follow-up of 48 months (12-147). 41 of the 58 patients submitted to 1st line treatment [median age 57 years (38-72), 36.2% male], underwent CT regimen containing Rituximab. The majority of these patients presented with follicular pattern and histological grade 1/2 (89.7%), 34.5% had FLIPI ≥ 3 and 50 % high tumor burden (GELF), 15.5% bulky mass, 53.4% had > 4 nodal areas involved and 6.9% > 1 extranodal area involved. 52 of the treated patients (89.7%) achieved CR and in 4 progression occurred (6.9%). 50 patients (86.2%) were alive without evidence of disease at the end of study (86.2%). In the group of patients undergoing surveillance, 11 suffered disease progression (52.4%), of which 10 (47.6%) stayed alive without evidence of disease. The TNT was higher in patients undergoing 1st CT regimen, compared to patients on WW (median 1480.5 vs. 765 months, p <0.001) with significant impact on PFS (p <0.001) but not on OS. Analyzing the treated subgroup, the addition of immunotherapy resulted in better TNT and PFS compared to WW (p <0.001), without affecting the OS. In univariate Cox regression analysis, the number of areas and extranodal tumor burden (GELF) were independent predictors of PFS and TNT (p <0.05). CONCLUSION: In asymptomatic patients with FL stage III-IV and high tumor burden, the CT especially when combined with immunotherapy, showed significant improvement on TNT and PFS compared to a WW approach, with no impact on OS. Despite a small sample group with retrospective data, our results are in agreement with the published literature. Disclosures No relevant conflicts of interest to declare." @default.
• W2566366120 created "2017-01-06" @default.
• W2566366120 creator A5002053930 @default.
• W2566366120 creator A5012491849 @default.
• W2566366120 creator A5012718986 @default.
• W2566366120 creator A5022072674 @default.
• W2566366120 creator A5022683649 @default.
• W2566366120 creator A5022683916 @default.
• W2566366120 creator A5024114732 @default.
• W2566366120 creator A5027874480 @default.
• W2566366120 creator A5031882530 @default.
• W2566366120 creator A5034189673 @default.
• W2566366120 creator A5034642807 @default.
• W2566366120 creator A5048853947 @default.
• W2566366120 creator A5049279419 @default.
• W2566366120 creator A5054897950 @default.
• W2566366120 creator A5056762017 @default.
• W2566366120 creator A5056921940 @default.
• W2566366120 creator A5057879270 @default.
• W2566366120 creator A5067739558 @default.
• W2566366120 creator A5076384027 @default.
• W2566366120 creator A5082458276 @default.
• W2566366120 creator A5089221056 @default.
• W2566366120 date "2014-12-06" @default.
• W2566366120 modified "2023-10-03" @default.
• W2566366120 title "Advanced Stage Follicular Lymphoma - Watch and Wait or Immunochemotherapy?" @default.
• W2566366120 doi "https://doi.org/10.1182/blood.v124.21.5476.5476" @default.
• W2566366120 hasPublicationYear "2014" @default.
• W2566366120 type Work @default.
• W2566366120 sameAs 2566366120 @default.
• W2566366120 citedByCount "0" @default.
• W2566366120 crossrefType "journal-article" @default.
• W2566366120 hasAuthorship W2566366120A5002053930 @default.
• W2566366120 hasAuthorship W2566366120A5012491849 @default.
• W2566366120 hasAuthorship W2566366120A5012718986 @default.
• W2566366120 hasAuthorship W2566366120A5022072674 @default.
• W2566366120 hasAuthorship W2566366120A5022683649 @default.
• W2566366120 hasAuthorship W2566366120A5022683916 @default.
• W2566366120 hasAuthorship W2566366120A5024114732 @default.
• W2566366120 hasAuthorship W2566366120A5027874480 @default.
• W2566366120 hasAuthorship W2566366120A5031882530 @default.
• W2566366120 hasAuthorship W2566366120A5034189673 @default.
• W2566366120 hasAuthorship W2566366120A5034642807 @default.
• W2566366120 hasAuthorship W2566366120A5048853947 @default.
• W2566366120 hasAuthorship W2566366120A5049279419 @default.
• W2566366120 hasAuthorship W2566366120A5054897950 @default.
• W2566366120 hasAuthorship W2566366120A5056762017 @default.
• W2566366120 hasAuthorship W2566366120A5056921940 @default.
• W2566366120 hasAuthorship W2566366120A5057879270 @default.
• W2566366120 hasAuthorship W2566366120A5067739558 @default.
• W2566366120 hasAuthorship W2566366120A5076384027 @default.
• W2566366120 hasAuthorship W2566366120A5082458276 @default.
• W2566366120 hasAuthorship W2566366120A5089221056 @default.
• W2566366120 hasConcept C126322002 @default.
• W2566366120 hasConcept C141071460 @default.
• W2566366120 hasConcept C143998085 @default.
• W2566366120 hasConcept C146357865 @default.
• W2566366120 hasConcept C151730666 @default.
• W2566366120 hasConcept C167135981 @default.
• W2566366120 hasConcept C2776694085 @default.
• W2566366120 hasConcept C2777058707 @default.
• W2566366120 hasConcept C2777910003 @default.
• W2566366120 hasConcept C2778336483 @default.
• W2566366120 hasConcept C2779338263 @default.
• W2566366120 hasConcept C2780653079 @default.
• W2566366120 hasConcept C2780739268 @default.
• W2566366120 hasConcept C2781413609 @default.
• W2566366120 hasConcept C71924100 @default.
• W2566366120 hasConcept C86803240 @default.
• W2566366120 hasConceptScore W2566366120C126322002 @default.
• W2566366120 hasConceptScore W2566366120C141071460 @default.
• W2566366120 hasConceptScore W2566366120C143998085 @default.
• W2566366120 hasConceptScore W2566366120C146357865 @default.
• W2566366120 hasConceptScore W2566366120C151730666 @default.
• W2566366120 hasConceptScore W2566366120C167135981 @default.
• W2566366120 hasConceptScore W2566366120C2776694085 @default.
• W2566366120 hasConceptScore W2566366120C2777058707 @default.
• W2566366120 hasConceptScore W2566366120C2777910003 @default.
• W2566366120 hasConceptScore W2566366120C2778336483 @default.
• W2566366120 hasConceptScore W2566366120C2779338263 @default.
• W2566366120 hasConceptScore W2566366120C2780653079 @default.
• W2566366120 hasConceptScore W2566366120C2780739268 @default.
• W2566366120 hasConceptScore W2566366120C2781413609 @default.
• W2566366120 hasConceptScore W2566366120C71924100 @default.
• W2566366120 hasConceptScore W2566366120C86803240 @default.
• W2566366120 hasLocation W25663661201 @default.
• W2566366120 hasOpenAccess W2566366120 @default.
• W2566366120 hasPrimaryLocation W25663661201 @default.
• W2566366120 hasRelatedWork W2060114997 @default.
• W2566366120 hasRelatedWork W2094068466 @default.
• W2566366120 hasRelatedWork W2360450663 @default.
• W2566366120 hasRelatedWork W2535604369 @default.
• W2566366120 hasRelatedWork W2585162903 @default.
• W2566366120 hasRelatedWork W2586774864 @default.
• W2566366120 hasRelatedWork W2587240478 @default.
• W2566366120 hasRelatedWork W2593350124 @default.
• W2566366120 hasRelatedWork W2606158293 @default.
• W2566366120 hasRelatedWork W2907033709 @default.
• W2566366120 hasRelatedWork W2917765821 @default.
• W2566366120 hasRelatedWork W2986894365 @default.

• next